Episode 19 - Making the Leap to Digital Pathology
This episode's guests: Dr. Cory Roberts
Our guest is Dr. Cory Roberts, CEO, Chairman and President of ProPath. He is a pathologist with over 20 years of experience in healthcare ranging from academic medicine to specialty private practice and currently leading ProPath, the largest 100% physician owned pathology and laboratory medicine diagnostic practice in the country.
This episode, we are talking about what it takes to go digital in a large group practice. In 2020, ProPath made the leap into digital pathology. We will discover what lessons were learned, what was the business case for digital pathology, what will move the needle ultimately in putting digital pathology into practice, and we will talk about industry forces and consolidation in the laboratory business and what the future is going to look like.
Sponsor
More About Cory A. Roberts, MD, MBA
Dr. Cory Roberts joined ProPath in 2000. He has served as President and Chairman of the Board since 2011. In addition to holding these positions, Dr. Roberts was further named as the first Chief Executive Officer of ProPath in 2017.
Dr. Roberts has over 20 years of experience in clinical and anatomic pathology, with a sub-specialization in gastrointestinal and hepatic pathology. Prior to joining ProPath, he was an Assistant Professor of Pathology and Director of the Residency Program at the University of Nebraska Medical Center. He has written four books, numerous peer-reviewed publications, book chapters, and abstracts; and has lectured widely in his sub-specialty and on topics related to the business of pathology.
Dr. Roberts obtained his B.S. in Biology from Morningside College, his M.D. from the University of Nebraska Medical Center and his M.B.A. from University of North Texas at Dallas. He also completed his training in anatomic and clinical pathology, and gastrointestinal and hepatic pathology at Nebraska. In addition to ProPath, he serves on the Boards of Directors of Morningside College and Reveal Biosciences, and as a laboratory industry consultant for Glenview Capital Management.”